Cerhum
Develops patient-specific 3D-printed bioceramic bone grafts with patented interconnected porous structures for maxillofacial surgery.
- CEO / Founder
- Grégory Nolens
- Team Size
- 11-50
- Stage
- Commercial
- Total Funding
- €3.5M
- Latest Round
- Venture Round
- Key Investors
- Noshaq, Wallonie Entreprendre (WE), and private investors
Technology & Products
Key Products
MyBone® Custom
Technological Advantage
Proprietary 3D printing process for bioceramics achieving high osteoconductivity and controlled porosity, leveraging 10+ years of R&D from Sirris.
Differentiation
Value Proposition
Provides highly osteoconductive bioceramics with a patented porous structure that optimizes vascularization and osteointegration, offering a less invasive alternative to autografts.
How They Differentiate
Focuses on bioceramic density and specific interconnected porosity for bone growth, differentiating from traditional autografts and allografts.
Market & Competition
Target Customers
Medical professionals and hospitals performing cranio-maxillo-facial surgery.
Industry Verticals
Medical; Electronics; Aerospace; Luxury goods
Competitors
Xilloc Medical, Bone3D, Lithoz
Growth & Milestones
Growth Metrics
Obtained CE Mark for MyBone in 2020; ISO 13485 certified; raised €2M in 2021 to expand commercial operations in Europe.
Major Milestones
2015: Company founded as Sirris spin-out; 2018: MyBone® Custom product announced at MEDICA/COMPAMED; ISO 13485-2016 certification achieved
Notable Customers
3D-Side